Skip to main content
  1. Right Decisions
  2. Neurology pathways
  3. Back
  4. Headache
  5. 7. Medication Overuse Guidance
Announcements and latest updates

Right Decision Service newsletter: April 2024

Welcome to the Right Decision Service (RDS) newsletter for April 2024. 

Issues with RDS and Umbraco access

Tactuum has been working hard to address the issues experienced during the last week. They have identified a series of three mitigation measures and put the first of these in place on Friday 3rd May.  If this does not resolve the problems, the second mitigation will be actioned, and then the third if necessary.

Please keep a lookout for any slowing down of the system or getting locked out. Please email myself, mbuchner@tactuum.com and onivarova@tactuum.com if you experience any problems, and also please raise an urgent support ticket via the Support Portal.

Thank you for your patience and understanding while we achieve a full resolution.

Promotion and communication resources

A rotating carousel presenting some of the key RDS tools and capabilities, and an editable slideset, are now available in the Resources for RDS providers section of the Learning and Support toolkit.

Redesign and improvements to RDS

The redesign of RDS Search and Browse is still on-track for delivery by mid-June 2024. We then plan to have a 3-week user acceptance testing phase before release to live. All editors and toolkit owners on this mailing list will be invited to participate in the UAT.

The archiving and version control functionality is also progressing well and we will advise on timescales for user acceptance testing shortly.

Tactuum is also progressing with the deep linking to individual toolkits within the mobile RDS app. There are several unknowns around the time and effort required for this work, which will only become clear as the work progresses. So we need to be careful to protect budget for this purpose.

New feature requests

These have all been compiled and effort estimated. Once the redesign work is complete, these will be prioritised in line with the remaining budget. We expect this to take place around late June.

Evaluation

Many thanks to those of you completed the value and impact survey we distributed in February. Here are some key findings from the 65 responses we received.

Figure 1: Impact of RDS on direct delivery of care

Key figures

  • 93% say that RDS has improved evidence-informed practice (high impact 62%; some impact 31%)
  • 91% report that RDS has improved consistency in practice (high impact 65%, some impact 26%)
  • 85% say that RDS has improved patient safety (high impact 59%, some impact 26%)
  • Although shared decision-making tools are only a recent addition to RDS, and only represent a small proportion of the current toolset, 85% of respondents still said that RDS had delivered impact in this area (53% high impact, 32% some impact.) 92% anticipate that RDS will deliver impact on shared decision-making in future and 85% believe it will improve delivery of personalised care in future.

Figure 2 shows RDS impact to date on delivery of health and care services

 

Key figures

These data show how RDS is already contributing to NHS reform priorities and supporting delivery of more sustainable care.

Saving time and money

  • RDS clearly has a strong impact on saving practitioner time, with 90% of respondents reporting that this is the case. 65% say it has a high impact; 25% say it has some impact on time-saving.
  • It supports devolved decision-making across the multi-professional team (85% of respondents)
  • 76% of respondents confirm that it saves money compared, for example, to investing in commercial apps (54% high impact; 22% some impact.)
  • 72% believe it has impacted already on saving money and reducing waste in the way services are delivered – e.g. reducing costs of referral management, prescribing, admissions.

Quality assurance and governance

  • RDS leads are clear that RDS has improved local governance of guidelines, with 87% confirming that this is the case. (62% high impact; 25% some impact.)

Service innovation and workforce development

  • RDS is a major driver for service innovation and improvement (83% of respondents) and has impacted significantly on workforce knowledge and skills (92% of respondents – 66% high impact; 26% some impact).

New toolkits

A few examples of toolkits published to live in the last month:

Toolkits in development

Some of the toolkits the RDS team is currently working on:

  • SARCS (Sexual Assault Response Coordination Service)
  • Staffing method framework – Care Inspectorate.
  • SIGN 171 - Diabetes in pregnancy
  • SIGN 158 – British Guideline on Management of Asthma. Selected sections will be incorporated into the RDS, and complemented by a new chronic asthma pathway being developed by SIGN, British Thoracic Society and NICE.
  • Clinical pathways from NHS Fife and NHS Lanarkshire

Please contact his.decisionsupport@nhs.scot if you would like to learn more about a toolkit. The RDS team will put you in touch with the relevant toolkit lead.

Quality audit of RDS toolkits

Thanks to all of you who have responded to the retrospective quality audit survey and to the follow up questions.  We still have some following up to do, and to work with owners of a further 23 toolkits to complete responses. An interim report is being presented to the HIS Quality and Performance Committee.

Implementation projects

Eight clinical services and two public library services are undertaking tests of change to implement the Being a partner in my care app. This app aims to support patients and the public to become active participants in Realistic Medicine. It has a strong focus on personalised, person-centred care and a library of shared decision aids, as well as simple explanations and videoclips to help the public to understand the aims of Realistic Medicine.  The tests of change will inform guidance and an implementation model around wider adoption and spread of the app.

With kind regards

Right Decision Service team

Healthcare Improvement Scotland

Warning

Background

Medication overuse headache (MOH) is defined as headache occurring on 15 or more days per month in a patient with a pre-existing primary headache and developing as a consequence of regular overuse of acute or symptomatic medication for 3 months. Not all patients taking frequent acute medication for the management of primary headache have MOH. MOH can develop in patients taking medication for other painful conditions. 

 

MOH most commonly occurs as a complication of the management of migraine, although it can occur in any primary headache disorder. It rarely occurs in cluster headache and if it does the patient usually also has migraine.  

 

Any acute or symptomatic medication taken for the management of primary headache can result in MOH, although the highest risk is with triptans and opioids. 

  • Simple analgesics (Aspirin, NSAIDs, Paracetamol) > 15 days per month 
  • Triptans, opioids and combination analgesics > 10 days per month 

Medication Overuse Headache: Prevention

When prescribing acute treatment in primary headache patients should be warned about the risk of medication overuse headache. This is particularly important in patients with migraine. In general the use of simple analgesics and triptans should be restricted to 8-10 days per month. The use of combination analgesics and opioids should be avoided. Preventative treatment should be considered early in patients with frequent headache.

 

In cluster headache, because the headaches are so severe and the risk of MOH very low, patients should be allowed to use up to 2 doses of a triptan per day (subcutaneous sumatriptan or nasal sumatriptan/ zolmatriptan). 

Medication Overuse Headache Investigation

Before diagnosing MOH it is important to consider other secondary causes of chronic daily headache and investigate appropriately. 

Medication Overuse Headache: Treatment Strategies

1. Explanation: 

Adequate explanation is the key to managing MOH. The patient should be made aware that frequent use of acute medication “winds up” the migraine process making it more likely to happen and results in chronic headache. MOH is a recognised complication of the management of headache and rationalising/stopping medication can improve headache. Patients should be aware that headache can worsen before it improves (re-bound headache) and that this can last for days/weeks. Headache may still require appropriate management with acute and preventative treatment following medication withdrawal. Resuming frequent acute medication use is likely to result in re-emergence of MOH. 

2. Medication withdrawal: 

Medication withdrawal is the recommended strategy in patients with MOH. For simple analgesics and triptans abrupt withdrawal is preferable. For combination analgesics (particularly those containing high dose codeine) and opioids gradual withdrawal is recommended. The patient should be warned to expect withdrawal headaches. Other symptoms commonly encountered include: nausea, sleep disturbance and anxiety. Anti-emetics should be considered during the withdrawal phase and patients advised to keep adequately hydrated. Patients overusing triptans can be expected to improve over 7-10 days and those overusing simple analgesics over 2-3 weeks, but improvement can take a few months. For those who cannot manage abrupt withdrawal rationalising acute medication to 2 days per week can be helpful.  

Because medication withdrawal usually results in improvement rather than cessation of headaches adding in or adjusting preventative medication at the same time as initiating withdrawal should be considered. 

3. Preventative treatment: 

The effectiveness of most oral preventative treatments is reduced in MOH and if a preventative treatment is started this should be combined with rationalisation of the overused medication. Topiramate, Botulinum Toxin A and CGRP monoclonal antibodies are less likely to be affected by medication overuse. 

Referral criteria to secondary care (Medication Overuse Headache)

In patients with Medication Overuse Headache an adequate explanation, trial of medication withdrawal and consideration of starting prophylactic treatment should be undertaken prior to referral into secondary care. 

References and further resources

Wakerly, B. Medication Overuse Headache. Practical Neurology. 2019;19:399-403 

SIGN 155 Pharmacological management of migraine – updated March 2023; includes clinician and patient guidelines 

url: Pharmacological management of migraine (sign.ac.uk)  

British Association for the Study of Headache (BASH) National Management System 2019; includes clinician and patient portals 

url: Headache UK 

Editorial Information

Last reviewed: 11/10/2023

Next review date: 01/04/2025